Aytu Biopharma (AYTU) Gross Margin (2014 - 2026)

Aytu Biopharma (AYTU) has 13 years of Gross Margin data on file, last reported at 61.23% in Q1 2026.

• Gross Margin for Q1 2026 came in at 61.23%, down 817.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 64.78% (down 604.0% YoY), and the FY2025 annual result was 69.04%, down 621.0% from the prior year.
• Gross Margin retreated to 61.23% in Q1 2026 per AYTU's latest filing, from 63.46% in the prior quarter.
• Over five years, Gross Margin peaked at 77.89% in Q4 2023 and troughed at 52.42% in Q1 2022.
• A 5-year average of 65.97% and a median of 66.14% in 2025 frame the typical range for Gross Margin.
• On a YoY basis, Gross Margin climbed as much as 1782 bps in 2024 and fell as far as 1140 bps in 2024.
• A 5-year view of Gross Margin shows it stood at 65.81% in 2022, then climbed by 18 bps to 77.89% in 2023, then dropped by 15 bps to 66.49% in 2024, then retreated by 5 bps to 63.46% in 2025, then decreased by 4 bps to 61.23% in 2026.
• Business Quant data shows AYTU's Gross Margin at 61.23% in Q1 2026, 63.46% in Q4 2025, and 66.14% in Q3 2025.